Hepatorenal Syndrome: Causes, Symptoms, and Treatments

Hepatorenal syndrome is a form of kidney failure that develops not because something is wrong with the kidneys themselves, but because advanced liver disease disrupts blood flow so severely that the kidneys effectively shut down. It occurs almost exclusively in people with end-stage cirrhosis or, less commonly, acute liver failure, and it carries one of the highest mortality rates of any complication of liver disease. The underlying mechanism involves a cascade of circulatory changes triggered by portal hypertension, and the condition requires urgent treatment with vasoconstrictors and albumin, though liver transplantation remains the only definitive cure.

What Goes Wrong in the Body

The story starts in the portal vein, the major vessel that carries blood from the intestines to the liver. In advanced cirrhosis, scarring raises the pressure in this vein dramatically. That elevated pressure triggers the release of vasodilating substances in the splanchnic circulation, the network of blood vessels supplying the gut. Those vessels widen, and blood pools in the abdominal organs instead of returning efficiently to the heart and the rest of the body.¹

The result is a kind of paradox: the total volume of blood in the body hasn’t changed, but the effective circulating volume drops because so much of it is sitting in dilated splanchnic vessels. Blood pressure falls. The body’s emergency response kicks in, activating the sympathetic nervous system, the renin-angiotensin-aldosterone system, and triggering the release of vasopressin. All of these attempt to raise blood pressure by constricting blood vessels elsewhere, and the kidneys are especially sensitive to that constriction.² The renal arteries clamp down, blood flow to the kidneys drops, and the kidneys’ filtering rate plummets. If the process is severe enough and sustained long enough, the kidneys fail.

There’s also a growing recognition that systemic inflammation plays a role. Advanced cirrhosis promotes bacterial translocation from the gut into the bloodstream, which fuels an inflammatory state that worsens circulatory dysfunction and may directly contribute to kidney injury.³ This is why infections, especially spontaneous bacterial peritonitis, are one of the most common triggers for an episode of hepatorenal syndrome.

Common Triggers

Hepatorenal syndrome rarely develops out of nowhere. It almost always follows a precipitating event in someone whose liver disease is already advanced. The most recognized triggers include:

Spontaneous bacterial peritonitis: Infection of the fluid that accumulates in the abdomen (ascites) is the single most studied trigger and can tip an already fragile circulation into kidney failure.
Gastrointestinal bleeding: A large bleed from varices drops blood volume acutely, worsening the existing underfilling problem.
Aggressive diuresis or large-volume paracentesis without albumin replacement: Removing too much fluid too fast from someone with cirrhosis can collapse their effective circulating volume.
Use of nephrotoxic drugs: Nonsteroidal anti-inflammatory drugs and certain antibiotics can push marginal kidneys over the edge.
Sepsis or other infections: Any systemic infection intensifies the inflammatory and circulatory dysfunction already present.

Recognizing these triggers matters because avoiding them is one of the few genuinely preventive strategies available. Prophylactic antibiotics in high-risk patients and giving albumin during large-volume paracentesis are standard practices aimed specifically at preventing hepatorenal syndrome.

How It Presents Clinically

Hepatorenal syndrome doesn’t announce itself with a unique set of symptoms the way, say, appendicitis does. Its hallmark is a rapid or gradual rise in serum creatinine, the standard blood marker of kidney function, in a patient who already has obvious signs of advanced liver disease. By definition, these patients already have cirrhosis with portal hypertension and almost always have ascites.

What the patient typically experiences is the combination of symptoms from liver failure and worsening kidney function: deepening fatigue, reduced urine output, worsening abdominal swelling, low blood pressure, and sometimes confusion from hepatic encephalopathy. The kidneys themselves look structurally normal on imaging and on biopsy, which is one of the defining features: this is a functional shutdown, not structural damage.⁴ That distinction has practical consequences, because it means the kidneys can potentially recover if the underlying circulatory problem is corrected.

How Doctors Classify and Diagnose It

The classification has shifted in recent years. Older literature divided hepatorenal syndrome into Type 1 (a rapid, aggressive form where creatinine doubles within two weeks) and Type 2 (a slower, more indolent decline in kidney function usually associated with refractory ascites). Current guidelines have moved toward aligning the diagnosis with general acute kidney injury staging criteria used for all hospitalized patients. The condition is now referred to as HRS-AKI, reflecting a rapid decline in kidney function, distinct from non-HRS causes of acute kidney injury in cirrhosis such as direct kidney damage from bile acids, drug toxicity, or simple dehydration.⁵

The diagnosis is largely one of exclusion. Clinicians first rule out other causes of kidney injury: they stop nephrotoxic drugs, treat any infection, and give a fluid challenge with intravenous albumin. If creatinine doesn’t improve after two days of albumin and the patient has no evidence of structural kidney disease (no blood or protein in the urine, normal kidney ultrasound), the diagnosis of HRS-AKI is made.

Researchers are working on biomarkers that could make the distinction more precise. Urinary NGAL, a protein released when kidney tubular cells are injured, has shown strong ability to differentiate true structural kidney damage from hepatorenal syndrome. A systematic review and meta-analysis of eight studies including over 1,100 patients with cirrhosis found that urinary NGAL and another marker called IL-18 discriminated well between patients with structural tubular injury and those with other types of kidney impairment.⁶ A more recent systematic review confirmed NGAL’s reliability for this purpose.⁷ These biomarkers aren’t yet part of routine clinical practice everywhere, but they’re increasingly available at larger centers and could reshape how quickly and accurately the diagnosis is made.

Drug Treatment With Vasoconstrictors and Albumin

Since the core problem is extreme vasodilation leading to kidney underperfusion, the pharmacological strategy is straightforward in concept: constrict those dilated blood vessels and expand the circulating volume. In practice, this means a vasoconstrictor drug combined with intravenous albumin.

Terlipressin, a vasopressin analogue, is the most studied drug for this purpose and the first-line treatment in most guidelines worldwide. A large randomized trial published in the New England Journal of Medicine found that about a third of patients given terlipressin achieved verified reversal of hepatorenal syndrome, compared with about 17% of those given placebo.⁸ A meta-analysis of randomized trials confirmed that terlipressin roughly doubled the likelihood of HRS reversal compared to placebo.⁹

Those numbers deserve some context, though. Doubling the reversal rate sounds impressive, but the absolute rates are sobering: you’re going from roughly one in six patients improving to about one in three. And the meta-analysis found no difference in survival at 90 days between terlipressin and placebo groups.⁹ Terlipressin also carries real risks. In the NEJM trial, respiratory failure occurred at a much higher rate in the terlipressin group, and death from respiratory disorders was reported in about 11% of terlipressin-treated patients versus 2% of the placebo group.⁸ This means careful patient selection is essential, particularly avoiding the drug in patients with significant respiratory compromise.

Terlipressin was approved in the United States only in 2022, and it remains unavailable in some settings. The main alternatives are norepinephrine (given as a continuous intravenous drip, requiring an ICU) and the combination of midodrine and octreotide (which can be given outside the ICU). Head-to-head data suggest norepinephrine is more effective than the midodrine/octreotide combination. One randomized trial found that about 58% of patients treated with norepinephrine responded, compared with 20% of those on midodrine/octreotide.¹⁰ A retrospective analysis confirmed that patients treated with norepinephrine were significantly more likely to meet the primary kidney-function endpoint than those on midodrine/octreotide.¹¹

Terlipressin has also been compared directly to midodrine/octreotide. A randomized trial found that about 70% of terlipressin-treated patients recovered kidney function versus roughly 29% in the midodrine/octreotide group.¹² The clinical picture that emerges is that midodrine/octreotide, while convenient because it doesn’t require ICU-level monitoring, is the least effective option. Terlipressin and norepinephrine both outperform it substantially, and where terlipressin isn’t available, norepinephrine with albumin is the stronger alternative.

TIPS as a Bridge Procedure

Transjugular intrahepatic portosystemic shunt, commonly known as TIPS, is a procedure where interventional radiologists create a channel within the liver connecting the portal vein to the hepatic vein, effectively bypassing the scarred liver tissue and lowering portal pressure. In patients with hepatorenal syndrome, this addresses one of the root causes: the elevated portal pressure driving splanchnic vasodilation.

Early studies showed promising results. In a small series of seven patients with Type 1 HRS who received TIPS, kidney function improved in six, with dramatic drops in serum creatinine and increases in kidney blood flow. The improvement in kidney function was accompanied by suppression of the overactivated vasoconstrictor systems.¹³ More recent data in patients with a chronic pattern of kidney dysfunction have confirmed that kidney function improves as early as one week after TIPS and the benefit is maintained over follow-up.¹⁴

TIPS is not suitable for everyone. It works best in patients whose liver function hasn’t deteriorated too far, because the procedure can worsen hepatic encephalopathy and puts additional strain on the liver. In very sick patients with high MELD scores, the risks often outweigh the benefits. It’s typically considered either as a bridge to transplantation or in selected patients who don’t respond to drug therapy.

Liver Transplantation as the Definitive Treatment

Because hepatorenal syndrome is fundamentally a consequence of liver failure, replacing the diseased liver is the only intervention that removes the root cause. After a successful liver transplant, the circulatory derangements resolve and kidney function usually recovers, at least partially. Five-year survival after transplantation for patients with hepatorenal syndrome can exceed 65%, which is a remarkable turnaround for a condition that carries near-total short-term mortality without treatment.¹⁵

One of the important questions is whether patients with HRS need a combined liver-kidney transplant or whether a liver transplant alone is enough. National registry data have shown that five-year survival was about 62% for combined liver-kidney recipients and about 50% for patients receiving an isolated liver transplant who had significantly elevated creatinine, though single-center experience has shown comparable outcomes between the groups.¹⁶ The challenge is predicting which patients’ kidneys will recover after a liver transplant alone and which have sustained enough damage that they’ll need a new kidney too. Current criteria try to make this distinction based on the duration and severity of kidney dysfunction before transplant, but the decision remains imperfect.

Research suggests that reversing hepatorenal syndrome with vasoconstrictor therapy before transplant may improve long-term post-transplant outcomes.¹⁵ This means aggressive medical management isn’t just about buying time on the waiting list; it may genuinely improve the patient’s odds even after they receive a new liver. Rapid diagnosis and prompt treatment initiation are considered essential for improving prognosis overall.¹⁷

Factors That Predict Who Survives

Prognosis in hepatorenal syndrome is grim overall, but it varies considerably depending on several measurable factors. A study analyzing survival predictors found that older age, a history of alcohol-related liver disease, shorter duration of treatment, and higher MELD scores were independently associated with worse outcomes.¹⁸ The MELD score, which combines bilirubin, creatinine, and INR into a single number reflecting liver disease severity, is the standard tool used both for prognosis and for transplant allocation priority.

Researchers have been exploring whether better prognostic models can be built. One group developed a new scoring system called GIMNS (incorporating gender, INR, mean corpuscular hemoglobin concentration, neutrophil percentage, and organ failure staging) that outperformed the MELD score in predicting outcomes in hepatorenal syndrome patients.¹⁹ Whether this or similar models will replace MELD in clinical practice remains to be seen, but the search reflects a real limitation of current tools: MELD was designed for transplant prioritization across all liver disease, not specifically for predicting outcomes in HRS.

Hepatorenal Syndrome in Children

Although the condition is overwhelmingly discussed in the context of adult cirrhosis, hepatorenal syndrome also affects children. It occurs in roughly 5% of children with chronic liver conditions before liver transplantation.²⁰ The underlying mechanism is the same as in adults: portal hypertension, splanchnic vasodilation, and compensatory renal vasoconstriction. Management follows similar principles, with fluid expansion, withdrawal of nephrotoxic drugs, and vasoconstrictor therapy with terlipressin and albumin. Liver transplantation remains the ideal treatment in pediatric cases as well.²⁰

Pediatric cases are less well studied simply because they are rarer, and much of the evidence used to guide treatment in children is extrapolated from adult trials. The precipitating factors are similar too, with gastrointestinal bleeding and spontaneous bacterial peritonitis being recognized triggers in children as in adults.

The Financial and Human Cost

Hepatorenal syndrome generates an outsized financial burden relative to how many patients it affects. A U.S. analysis estimated about 27,180 HRS-related hospitalizations in 2019 alone, accounting for a total economic burden of roughly $4.2 billion.²¹ The average total hospital charge per patient was over $90,000, with a mean hospital stay of about 30 days.²² Hemodialysis, when required, drives a large share of the cost. A study from an intensive care setting found that dialysis costs alone accounted for a substantial portion of total hospitalization expenses.²³

These numbers underscore a broader reality about advanced liver disease: the complications of cirrhosis, not just the liver failure itself, are what consume healthcare resources. HRS represented about 16.5% of acute kidney injury cases among patients hospitalized with cirrhosis, making it one of the most common forms of kidney failure in that population.²¹

Living With the Diagnosis

The medical literature on hepatorenal syndrome focuses overwhelmingly on acute management, survival rates, and transplant outcomes. Relatively little attention has been paid to what life looks like for patients who survive an episode. A recent study that directly assessed quality of life and psychological distress in HRS survivors found high rates of anxiety and depression, along with significant impairment in physical and social functioning. When asked about treatment preferences in the event of future deterioration, about half favored intensive care, a small minority preferred a purely palliative approach, and roughly 40% were undecided.²⁴

That 40% who didn’t know what they would choose points to something meaningful: many patients with hepatorenal syndrome have never had a structured conversation about goals of care. They’re often caught between hoping for a transplant and recognizing how sick they are. Integrating psychological support and advance care planning into the management of HRS, rather than treating it purely as a medical emergency to be solved with drugs and procedures, is an area where clinical practice still has a long way to go.

1
PubMed Central. Hepatorenal Syndrome
2
Clinical Gastroenterology and Hepatology. Hepatorenal Syndrome–Acute Kidney Injury: Pathophysiology and Management
3
PubMed. Ascites, spontaneous bacterial peritonitis and hepatorenal syndrome – Complications of circulatory failure in cirrhosis
4
Nature Reviews Disease Primers. Hepatorenal syndrome
5
PubMed. Epidemiology, Pathophysiology, and Management of Hepatorenal Syndrome
6
PubMed Central. Urine Interleukin 18 and Lipocalin 2 Are Biomarkers of Acute Tubular Necrosis in Patients With Cirrhosis: A Systematic Review and Meta-analysis
7
PubMed Central. Clinical diagnosis and biomarkers of acute kidney injury in liver cirrhosis: a systematic review
8
PubMed. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome
9
PubMed Central. Terlipressin effect on hepatorenal syndrome: Updated meta‐analysis of randomized controlled trials
10
PubMed Central. Norepinephrine is More Effective Than Midodrine/Octreotide in Patients With Hepatorenal Syndrome-Acute Kidney Injury: A Randomized Controlled Trial
11
PubMed Central. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
12
PubMed. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial
13
PubMed. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems
14
PubMed. Transjugular intrahepatic porto-systemic shunt in cirrhotic patients with hepatorenal syndrome – chronic kidney disease: Impact on renal function
15
Frontiers of Gastrointestinal Research. Hepatorenal syndrome and liver transplantation
16
PubMed. Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant
17
PubMed. Hepatorenal syndrome, MELD score and liver transplantation: an evolving issue with relevant implications for clinical practice
18
PubMed Central. Hepatorenal syndrome: outcome of response to therapy and predictors of survival
19
PubMed Central. Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study
20
PubMed Central. Hepatorenal syndrome in children: a review
21
Alimentary Pharmacology and Therapeutics. Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US
22
PubMed. The burden of illness of hepatorenal syndrome (HRS) in the United States: a retrospective analysis of electronic health records
23
PubMed Central. Hepatorenal Syndrome: direct treatment costs and characteristics of patients admitted to intensive care
24
PubMed Central. Life after hepatorenal syndrome: unraveling quality of life, psychological distress, and treatment preferences